Literature DB >> 12612090

mRNA instability in the nucleus due to a novel open reading frame element is a major determinant of the narrow tissue specificity of folate receptor alpha.

Xuan Zheng1, Karen Kelley, Hala Elnakat, Wu Yan, Ted Dorn, Manohar Ratnam.   

Abstract

The folate receptor type alpha (FR-alpha) is a promising tumor marker and target. Here, we investigate the mechanistic basis for the tumor specificity and vast overexpression of FR-alpha. Among representative FR-alpha-positive (HeLa and JAR) and FR-alpha-negative (MG63, Caki1, and HT3) cell lines, the transcription rates of the endogenous FR-alpha gene, as well as the FR-alpha promoter activity, were relatively weak and comparable, but the FR-alpha transcript was abundant only in total RNA and nuclear RNA from the FR-alpha-positive cells. Rous sarcoma virus (RSV) promoter-driven expression of the FR-alpha gene was 7 to 30 times greater in the FR-alpha-positive than in FR-alpha-negative cells, both at the protein and mRNA levels, independently of intron sequences. Through the use of chimeric FR-alpha/FR-beta cDNAs, the above pattern of FR-alpha expression was attributed to a 60-bp sequence in the FR-alpha open reading frame. This sequence element, when placed in the 5' untranslated region of RSV promoter-luciferase, decreased the reporter expression approximately 7- to 20-fold in FR-alpha-negative cells (MG63, Caki1, HT3, BG1, and MCF7) relative to FR-alpha-positive cells (HeLa, JAR, and JEG3). Substitution of this FR-alpha element in FR-beta increased the in vivo degradation rate of the transcript in the nuclei of MG63 cells but not in the nuclei of HeLa cells or in the cytosol of MG63 or HeLa cells. The results reveal an efficient mechanism by which a novel sequence element causes differential transcript degradation in the nucleus to ensure narrow tissue specificity for a gene (e.g., that for FR-alpha) whose transcription is weak and relatively nonselective. FR-alpha exhibited constitutive mRNA and protein synthesis during the cell cycle and a slow protein turnover, presumably ensuring a high steady-state level of the receptor in cells that could override the nuclear mRNA instability determinant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612090      PMCID: PMC149483          DOI: 10.1128/MCB.23.6.2202-2212.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  38 in total

1.  The specific endoribonuclease activity of small nuclear and cytoplasmic alpha-RNPs.

Authors:  I M Konstantinova; V A Kulichkova; I N Evteeva; A G Mittenberg; I V Volkova; J B Ermolaeva; L N Gause
Journal:  FEBS Lett       Date:  1999-12-03       Impact factor: 4.124

2.  Overexpression of folate binding protein in ovarian cancers.

Authors:  G Toffoli; C Cernigoi; A Russo; A Gallo; M Bagnoli; M Boiocchi
Journal:  Int J Cancer       Date:  1997-04-22       Impact factor: 7.396

3.  Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.

Authors:  G E Peoples; B W Anderson; T V Lee; J L Murray; A P Kudelka; J T Wharton; C G Ioannides
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

4.  Tissue-specific promoters of the alpha human folate receptor gene yield transcripts with divergent 5' leader sequences and different translational efficiencies.

Authors:  S J Roberts; K N Chung; K Nachmanoff; P C Elwood
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

5.  Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA.

Authors:  M Ratnam; H Marquardt; J L Duhring; J H Freisheim
Journal:  Biochemistry       Date:  1989-10-03       Impact factor: 3.162

6.  Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.

Authors:  R M Luiten; S O Warnaar; D Sanborn; C H Lamers; R L Bolhuis; S V Litvinov; V R Zurawski; L R Coney
Journal:  J Immunother       Date:  1997-11       Impact factor: 4.456

Review 7.  Targeted drug delivery via the folate receptor.

Authors:  J Sudimack; R J Lee
Journal:  Adv Drug Deliv Rev       Date:  2000-03-30       Impact factor: 15.470

8.  Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia.

Authors:  J F Ross; H Wang; F G Behm; P Mathew; M Wu; R Booth; M Ratnam
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

9.  Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal.

Authors:  W Yan; M Ratnam
Journal:  Biochemistry       Date:  1995-11-07       Impact factor: 3.162

10.  Dihydrofolate reductase gene expression in cultured mouse cells is regulated by transcript stabilization in the nucleus.

Authors:  E J Leys; G F Crouse; R E Kellems
Journal:  J Cell Biol       Date:  1984-07       Impact factor: 10.539

View more
  4 in total

1.  Inhibitory cis-element-mediated decay of human papillomavirus type 16 L1-transcript in undifferentiated cells.

Authors:  Seiichiro Mori; Saori Ozaki; Toshiharu Yasugi; Hiroyuki Yoshikawa; Yuji Taketani; Tadahito Kanda
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

2.  Androgen activation of the folate receptor α gene through partial tethering of the androgen receptor by C/EBPα.

Authors:  Suneethi Sivakumaran; Juan Zhang; Karen M M Kelley; Mesfin Gonit; Hong Hao; Manohar Ratnam
Journal:  J Steroid Biochem Mol Biol       Date:  2010-09-15       Impact factor: 4.292

3.  Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.

Authors:  Zhanjun Hou; Leda Gattoc; Carrie O'Connor; Si Yang; Adrianne Wallace-Povirk; Christina George; Steve Orr; Lisa Polin; Kathryn White; Juiwanna Kushner; Robert T Morris; Aleem Gangjee; Larry H Matherly
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

4.  Multifunctional Fe3O4 @ Au core/shell nanostars: a unique platform for multimode imaging and photothermal therapy of tumors.

Authors:  Yong Hu; Ruizhi Wang; Shige Wang; Ling Ding; Jingchao Li; Yu Luo; Xiaolin Wang; Mingwu Shen; Xiangyang Shi
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.